A pharmacovigilance study on steroid induced osteoporosis Mohammed Taqui1,*, Swamivelmanickam M.2,**, Billah A Mohathasim3,*** 1PhD Scholar, Department of Pharmacy, Annamalai University, Chidambaram, Tamil Nadu, India 2Associate Professor, Department of Pharmacy, Annamalai University, Chidambaram, Tamil Nadu, India 3Department of Pharmacy, Sri Indu Institute of Pharmacy, Hyderabad, Telangana, India *Corresponding Author E-mail: taquipharma@gmail.com
**swamivel@yahoo.com
***billahs@yahoo.co.uk
Online Published on 5 February, 2024. Abstract Background In elderly people, osteoporosis and low bone density are significant risk factors for morbidity and death. Low bone strength distinguishes these illnesses, which are correlated to an increased risk of fractures from even minor traumas. Objectives To study pharmacovigilance on steroid induced osteoporosis. Methods A total of 950 individual who were diagnosed with osteoporosis. These individuals were deemed to be at a high risk of osteoporosis. Patients were given information regarding the risks of steroid-induced osteoporosis, as well as a handout. The patient's steroid duration and any medicines used to control the risks of steroid-induced osteoporosis were the focus of the initial evaluation. Following that, evaluations of the pharmacological therapy being examined. Any problems found were discussed with the patient and/or the prescribing practitioner. Data was gathered at the start of the study and again after 6 months of observation. Results Glucocorticoids (prednisolone) was the main prescription drug of the entire study sample. Family history of Osteoporosis was reported in 20% of the cases. The history of fracture was reported in 30% of the cases. Low calcium diet was reported in 35% of the cases. Osteoporosis was diagnosed in 17% of the cases, Osteopenia in 22% of the cases. In 88% of the cases the drug prescribed was >5mg daily. The duration of CS intake was high. This shows that the CS drug is being abused mostly in history of allergies and asthma as its easily available OTC leading to an increased risk of osteoporosis. Around 26% were prescribed antiosteoporosis treatment with Bisphosphonate. Estrogen therapy was prescribed in 16% of the cases. Calcium supplement consumption was increased by 17%. There was significant reduction in BMD, Glucocorticoid’s usage and daily dosage and result was statistically significant. Conclusion Because all cells employ the same glucocorticoid receptor, corticosteroids' antiinflammatory effects cannot be distinguished from their metabolic effects; thus, precautions should be taken when corticosteroids are given. Clearly, the risk of serious adverse effects rises as the amount and duration of therapy increases, thus the smallest dose required to control the condition should be provided. Top Keywords Osteoporosis, Glucocorticoids, Bisphosphonate, Corticosteroids. Top |